Freedom of Information Request ID
7273
Date of response
April 2022
Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
Bevacizumab (Avastin)
Dacarbazine (DTIC)
Trametinib (Mekinist)
Dabrafenib (Tafinlar)
Ipilimumab (Yervoy)
Vemurafenib (Zelboraf)
Nivolumab (Opdivo)
Nivolumab + Ipilimumab (Opdivo + Yervoy)
Pembrolizumab (Keytruda)
Vemurafenib + cobimetinib (Zelboraf + Cotellic)
Dabrafenib + Trametinib (Tafinlar + Mekinist)
Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
Other active systemic anti-cancer therapy [please state]
Palliative care only
*Please see below.
Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
Ipilimumab
Ipilimumab AND Nivolumab
Nivolumab
Pembrolizumab
Dabrafenib AND Trametinib
Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
Other active systemic anti-cancer therapy
Palliative care only
*Medway NHS Foundation regret this data is not collated. The Trust’s Pharmacy department can confirm the number of patients that have been issued the drug, but pharmacy do not hold details of the indication that each drug was prescribed for. Therefore please see below data held for the reporting period 01/01/2022 to 31/03/2022 for all indications, not just melanoma patients. If the drug is not listed, it is because it has not been issued.
DACARBAZINE
Number of patients: <5
IPILIMUMAB (YERVOY)
Number of patients: <5
NIVOLUMAB (OPDIVO)
Number of patients: 10
PEMBROLIZUMAB
Number of patients: 39
FOI Requests
The Freedom of Information Act 2000 provides people with a right of access to a wide range of information held by public authorities, including the NHS.
FOI Disclosure Log
A collection of the most common FOI requests we have received and responded to.